Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma

Francesca Gay, S. Vincent Rajkumar, Morton Coleman, Shaji Kumar, Tomer Mark, Angela Dispenzieri, Roger Pearse, Morie A. Gertz, John Leonard, Martha Q. Lacy, Selina Chen-Kiang, Vivek Roy, David S. Jayabalan, John A. Lust, Thomas E. Witzig, Rafael Fonseca, Robert A. Kyle, Philip R. Greipp, A. Keith Stewart, Ruben Niesvizky

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences